You are here: Industry Insights > Novo Nordisk

News List

Novo Nordisk receives FDA nod for haemophilia A drug Esperoct pharmaceutical-technology
February 22, 2019
Danish Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for its drug Esperoct (turoctocog alfa pegol, N8-GP) indicated for haemophilia A treatment in both adults and children.....
Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin worldpharmanews
February 21, 2019
Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk...
Novo Nordisk signs dyslipidaemia drug deal with Staten Biotechnology pharmaceutical-technology
December 19, 2018
Novo Nordisk has signed a collaboration and exclusive option agreement with Dutch drug maker Staten Biotechnology for the development of new therapies to treat hypertriglyceridaemia......
Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes pharmaceutical-technology
December 12, 2018
Novo Nordisk has entered into research collaboration with UK-based E-therapeutics for the development of new treatment strategies for a specific area of type-2 diabetes.....
Novo keeps adding capacity, and jobs, to its North Carolina drug plant fiercepharma
December 06, 2018
Just months after announcing a $65 million expansion that will boost capacity at the North Carolina facility where it makes diabetes medications, Novo Nordisk says it needs yet more...
Novo Nordisk's semaglutide is headed toward a Lilly showdown. Will Novo speed it up? fiercepharma
December 05, 2018
Novo Nordisk’s oral semaglutide is heading toward a market shake-up. And the company wants to see that happen sooner rather than later.
Novo Nordisk launches type II diabetes awareness campaign pharmatimes
November 29, 2018
Novo Nordisk UK is launching a campaign to raise awareness of the risk of heart attacks and strokes in people living with type II diabetes.
Novo Nordisk’s diabetes pill clears cardiac safety hurdle pharmaphorum
November 28, 2018
Novo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase 3 trial assessing its cardiac safety, with results showing it also reduced risk of cardiovascular and all-causes death in high-risk patients.
Novo Nordisk cuts 1300 jobs in the midst of Trump's pricing pressures and depreciation of US dollar pharmafile
November 20, 2018
Danish multinational Novo Nordisk has said that they will have cut 1,300 employees by the end of 2018. The decision has come partly in response to the Trump administration’s
Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease worldpharmanews
November 10, 2018
Embark Biotech ApS and Novo Nordisk A/S have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page